The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Gabapentin Is a First Line Drug for the Treatment of Neuropathic Pain in Spinal Cord Injury
Abstract
In Brief Study Design. Prospective, randomized, double blind, placebo-controlled, crossover clinical trial. Objectives. To determine the efficacy of gabapentin in the treatment of neuropathic pain related to spinal cord injury. Summary of Background Data. Neuropathic pain is initiated or caused by a primary lesion or dysfunction in the nervous system. Neuropathic pain associated with spinal cord injury is quite refractory, and current treatments are not effective. Gabapentin, an anticonvulsant, has become the first choice in the treatment of neuropathic pain. The place of gabapentin in the treatment of spinal cord injury-related neuropathic pain was questioned in only a few recent reports; however, they are retrospectively designed, nonstandardized, and uncontrolled studies, or involve a very small series of patients using less than optimum doses. Methods. A total of 18-week study period included a 4-week medication/placebo titration period. This was followed by a 4-week stable dosing period when the patients continued to receive maximum tolerated doses, a 2-week washout period, then a crossover of 4 weeks of medication/placebo titration, and another 4 weeks of stable dosing period. Twenty paraplegic patients (female/male: 7/13) with complete spinal cord injury at the thoracic and lumbar level, aged between 20 and 65 years, with neuropathic pain for more than 6 months were recruited for the study. Results. All patients completed the study. Gabapentin reduced the intensity as well as the frequency of pain, relieved all neuropathic pain descriptors except the itchy, sensitive, dull, and cold types, and improved the quality of life (P < 0.05). Conclusions. Gabapentin can be added to the list of first-line medications for the treatment of chronic neuropathic pain in spinal cord injury patients. It is a promising new agent and offers advantages over currently available treatments. A prospective, randomized, double blind, placebo-controlled, crossover clinical trial was undertaken to determine the effi- cacy of gabapentin in the treatment of neuropathic pain related to spinal cord injury. Gabapentin reduced the intensity, as well as, the frequency of pain, relieved all neuropathic pain descriptors except the itchy, sensitive, dull and cold types, and improved the quality of life.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The McGill Pain Questionnaire: Major properties and scoring methods
Melzack, R. (1975) · Pain · doi:10.1016/0304-3959(75)90044-5 · Cited by 6,845
Backonja, M. (1998) · JAMA · doi:10.1001/jama.280.21.1831 · Cited by 1,533
Rowbotham, M. (1998) · JAMA · doi:10.1001/jama.280.21.1837 · Cited by 1,433
Sindrup, S. H., & Jensen, T. S. (1999) · Pain · doi:10.1016/s0304-3959(99)00154-2 · Cited by 1,144
A systematic review of antidepressants in neuropathic pain
McQuay, H. J., Tramér, M., Nye, B. A., Carroll, D., Wiffen, P. J., & Moore, R. A. (1996) · Pain · doi:10.1016/s0304-3959(96)03140-5 · Cited by 930
Gabapentin in neuropathic pain syndromes: a randomised, double-blind, placebo-controlled trial
Serpell, M. G. (2002) · Pain · doi:10.1016/s0304-3959(02)00255-5 · Cited by 433
Rintala, D. H., Loubser, P. G., Castro, J., Hart, K. A., & Fuhrer, M. J. (1998) · Archives of Physical Medicine and Rehabilitation · doi:10.1016/s0003-9993(98)90032-6 · Cited by 275
Chronic pain associated with spinal cord injuries: A community survey
Turner, J. A., Cardenas, D. D., Warms, C. A., & McClellan, C. B. (2001) · Archives of Physical Medicine and Rehabilitation · doi:10.1053/apmr.2001.21855 · Cited by 271
Chronic pain/dysaesthesiae in spinal cord injury patients: results of a multicentre study
Störmer, S., Gerner, H. J., Grüninger, W., Metzmacher, K., Föllinger, S., Wienke, C., Aldinger, W., Walker, N., Zimmermann, M., & Paeslack, V (1997) · Spinal Cord · doi:10.1038/sj.sc.3100411 · Cited by 231
Tai, Q., Kirshblum, S., Chen, B., Millis, S., Johnston, M., & DeLisa, J. A. (2002) · The Journal of Spinal Cord Medicine · doi:10.1080/10790268.2002.11753609 · Cited by 208
Cited by
Pharmacologic management of neuropathic pain: Evidence-based recommendations
Dworkin, R. H., O’Connor, A. B., Backonja, M., Farrar, J. T., Finnerup, N. B., Jensen, T. S., Kalso, E. A., Loeser, J. D., Miaskowski, C., Nurmikko, T. J., et al. (2007) · Pain · doi:10.1016/j.pain.2007.08.033 · Cited by 2,126
EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision
Attal, N., Cruccu, G., Baron, R., Haanpää, M., Hansson, P., Jensen, T. S., & Nurmikko, T. (2010) · European Journal of Neurology · doi:10.1111/j.1468-1331.2010.02999.x · Cited by 1,873
Algorithm for neuropathic pain treatment: An evidence based proposal
Finnerup, N. B., Otto, M., McQuay, H. J., Jensen, T. S., & Sindrup, S. H. (2005) · Pain · doi:10.1016/j.pain.2005.08.013 · Cited by 1,330
EFNS guidelines on pharmacological treatment of neuropathic pain
Attal, N., Cruccu, G., Haanpää, M., Hansson, P., Jensen, T. S., Nurmikko, T., Sampaio, C., Sindrup, S., & Wiffen, P. (2006) · European Journal of Neurology · doi:10.1111/j.1468-1331.2006.01511.x · Cited by 880
Gabapentin for chronic neuropathic pain and fibromyalgia in adults
Moore, R. A., Wiffen, P. J., Derry, S., & McQuay, H. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007938.pub2 · Cited by 690
Metadata
- Authors
- Levendoğlu, F., Öğün, C. Ö., Özerbil, Ö., Öğün, T. C., & Uğurlu, H.
- Venue
- Spine
- Published
- 2004-04
- Volume
- 29
- Issue
- 7
- Pages
- 743-751
- ISSN
- 0362-2436 (ISSN-L)
- OpenAlex
- W2093050196
- Cited by
- 267
- References
- 24
- FWCI
- 12.16
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gabapentin Is a First Line Drug for the Treatment of Neuropathic Pain in Spinal Cord Injury. https://app.cochat.ai/papers/10.1097/01.brs.0000112068.16108.3a
- The paper
- Levendoğlu, F., Öğün, C. Ö., Özerbil, Ö., Öğün, T. C., & Uğurlu, H. (2004). Gabapentin Is a First Line Drug for the Treatment of Neuropathic Pain in Spinal Cord Injury. Spine. https://doi.org/10.1097/01.brs.0000112068.16108.3a
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.